COLORADO SPRINGS, Colo., Feb. 12 /PRNewswire-FirstCall/ -- Spectranetics Corporation announced today that it has hired Jeffrey Deming as Vice President of Quality Assurance and Regulatory Compliance. Mr. Deming replaces Adrian Elfe, who will be retiring following a transition period.
Mr. Deming comes to Spectranetics with over 17 years experience within the healthcare sector, most recently as the Director of Quality Assurance and Regulatory Affairs at Tyco Healthcare/Surgical. Prior to his tenure at Tyco, he held leadership positions within the healthcare consulting and clinical industries. Mr. Deming holds a BS in Healthcare Administration from Hahnemann University, as well as Masters and Doctorate degrees in Healthcare Administration from Bienville University.
“We are very pleased to have Jeff Deming join the management team at Spectranetics. Quality assurance is a critical aspect in the planned expansion of our product line and our ability to address new markets. Jeff has an outstanding track record in management and planning, and he will play an important role in the growth of our operations,” said John G. Schulte, Spectranetics’ President and Chief Executive Officer. “I also want to express my thanks to Adrian Elfe for 17 years of outstanding service to Spectranetics, and for the contributions he has made to the growth and success of the Company.”
Spectranetics also announced it has promoted Vice President of Sales Stephen Okland to the position of Vice President of Sales and Marketing for the United States. “Since joining the Company last February, Steve has led the expansion and improvement of our sales organization, and we are confident he will enjoy the same success with his additional marketing responsibilities,” said Schulte. Mr. Okland has 19 years experience in the medical device industry, including several sales, marketing and senior management positions. During 12 years with Boston Scientific Corporation, he held various positions of increasing responsibility, most recently as director of sales and group marketing manager in the urology division.
About Spectranetics
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Excimer laser technology delivers relatively cool ultraviolet energy to ablate or remove arterial blockages including plaque, calcium and thrombus. We believe our CVX-300(R) excimer laser is the only system approved in the United States, Europe, Japan, and Canada for use in multiple, minimally invasive cardiovascular procedures. These procedures include atherectomy, which is a procedure to remove arterial blockages in the peripheral or coronary vasculature, and the removal of infected, defective or abandoned cardiac lead wires from patients with pacemakers or implantable cardiac defibrillators, or ICDs, which are electronic devices that regulate the heartbeat.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company’s strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company’s previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.
COMPANY CONTACT: INVESTOR & MEDIA CONTACTS: Spectranetics Corporation Lippert/Heilshorn & Associates, Inc. Guy Childs, Chief Financial Officer Bruce Voss (719) 633-8333 Don Markley (310) 691-7100 www.spectranetics.comwww.lhai.com
Spectranetics Corporation
CONTACT: Guy Childs, Chief Financial Officer of Spectranetics Corporation,+1-719-633-8333; or Investors and Media, Bruce Voss or Don Markley, both ofLippert/Heilshorn & Associates, Inc., +1-310-691-7100, for SpectraneticsCorporation
Web site: http://www.spectranetics.com/
